This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective Data regarding the efficacy and safety of warfarin and non-vitamin K antagonist oral anticoagulant (NOAC) among patients with chronic kidney disease (CKD) remain scarce.
Methods Systematic review and meta-analysis of studies involving patients with CKD treated with oral anticoagulants were conducted to evaluate the following outcomes: ischemic stroke, intracerebral hemorrhage (ICH), combined ischemic and hemorrhagic stroke (strokecombined), stroke or systemic embolism, mortality, and major bleeding events. CKD was defined based on creatinine clearance (CrCl) ranging from mild (CrCl: 60–89 mL/min), moderate (CrCl: 30–59 mL/min), to severe (CrCl: 15–29 mL/min).
Results Fifteen studies (7 comparing NOAC vs warfarin and 8 comparing warfarin vs no anticoagulant) were identified comprising 78,053 patients. Warfarin (vs no anticoagulant) was associated with reduced risk of ischemic stroke (risk ratio [RR] = 0.68; 95% confidence interval [CI] 0.55–0.84]) and mortality (RR = 0.70; 95% CI 0.62–0.78). In comparison to warfarin, NOAC use lowered the risk of ICH (RR = 0.43; 95% CI 0.33–0.56), strokecombined (RR = 0.83; 95% CI 0.72–0.96), stroke or systemic embolism (RR = 0.73; 95% CI 0.62–0.85), and major bleeding (RR = 0.77; 95% CI 0.66–0.90). In adjusted analyses, warfarin use (vs no anticoagulant) was associated with reduced mortality (HRadj = 0.68; 95% CI 0.61–0.76), whereas NOAC (vs warfarin) use reduced the risk of ICH (HRadj = 0.39; 95% CI 0.30–0.50) and stroke or systemic embolism (HRadj = 0.75; 95% CI 0.65–0.88). Our sensitivity analyses comparing different NOACs exhibited that factor Xa inhibitors (compared to warfarin) consistently reduced strokecombined (RR = 0.84; 95% CI 0.73–0.96), mortality (RR = 0.84; 95% CI 0.70–1.00), ICH (RR = 0.45; 95% CI 0.24–0.85), and major bleeding (RR = 0.76; 95% CI 0.64–0.91).
Conclusions Among patients with CKD treated with oral anticoagulants, NOACs present with a more favorable safety and efficacy profile for various cardiovascular outcomes.
Glossary
- CI=
- confidence interval;
- CKD=
- chronic kidney disease;
- CrCl=
- creatinine clearance;
- eGFR=
- estimated glomerular filtration rate;
- HR=
- hazard ratio;
- HRadj=
- adjusted hazard ratio;
- ICH=
- intracerebral hemorrhage;
- NOAC=
- non-vitamin K antagonist oral anticoagulant;
- OAC=
- oral anticoagulant;
- RCT=
- randomized-controlled trial;
- RR=
- risk ratio;
- strokecombined=
- combined ischemic and hemorrhagic stroke
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
CME Course NPub.org/cmelist
- Received September 11, 2018.
- Accepted in final form January 19, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
